M&A Deal Summary |
|
|---|---|
| Date | 2020-02-10 |
| Target | Valeritas |
| Sector | Medical Products |
| Buyer(s) | Zealand Pharma |
| Deal Type | Special Situations/Distressed |
| Deal Value | 23M USD |
| Advisor(s) | Lincoln International (Financial) DLA Piper PwC Law (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1997 |
| Sector | Life Science |
| Employees | 440 |
| Revenue | 63M DKK (2024) |
Zealand Pharma is a biotechnology company specializing in the discovery and development of peptide-based medicines for metabolic and gastrointestinal diseases. The company advances both proprietary and partnered therapeutics, using peptide engineering to deliver innovative treatments to patients. Zealand Pharma was founded in 1997 and is headquartered in Soborg, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Special Situations/Distressed M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |